Incurred sample reanalysis [Regulatives / Guidelines]

posted by sarada06884 – India, 2013-04-09 14:22 (4436 d 17:38 ago) – Posting: # 10381
Views: 16,538

Hi Helmut,

Incurred sample reanalysis has been suggested by USFDA but I would like to debate on this topic.

How are ISR samples different from subject samples? The answer would be they are in vivo samples and the QCs are in vitro samples. ISR samples are meant for demonstrating assay reproducibility. Based on this now my concern would be:
  1. When the whole validation has been done based on in vitro samples and when the results of these experiments have been accepted then why ISR again?
  2. When Long Term Matrix Stability of the drug and metabolites are proven taking invitro samples is proven and when the stability of such experiment is accepted then why ISR again?
  3. Even though the ISR samples are reanalysed they are analysed along with CCs and QCs which are invitro again!!!!
  4. What if ISR fails?? probably they have to ascertain the cause and go for the development of the method again?????
Please give me your views

Regards
Srinivas

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,678 registered users;
18 visitors (0 registered, 18 guests [including 17 identified bots]).
Forum time: 08:01 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5